Yiqi Zhuyu Decoction (益气逐瘀汤) Combined with FOLFOX-4 as first-line therapy in metastatic colorectal cancer

Bo Cao; Shao-tang Li; Zhi Li; Wen-ling Deng

doi:10.1007/s11655-011-0822-z

Your Location：

Home >

Browse articles >

Yiqi Zhuyu Decoction (益气逐瘀汤) Combined with FOLFOX-4 as first-line therapy in metastatic colorectal cancer

Updated：2021-08-27

- Yiqi Zhuyu Decoction (益气逐瘀汤) Combined with FOLFOX-4 as first-line therapy in metastatic colorectal cancer
- Chinese Journal of Integrative Medicine Vol. 17, Issue 8, Pages: 593-599(2011)
- Affiliations：
  
  1. Department of Colorectal and Anal Surgery, the First Affiliated Hospital of Guiyang College of Traditional Chinese Medicine,Guiyang,China
  2. Department of Colorectal Surgery, Xinhua Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Colorectal Cancer Center of Shanghai Jiaotong University,Shanghai,China
- Author bio：
- Funds：
- DOI：10.1007/s11655-011-0822-z
  CLC：
- Published：2011，
  
  Published Online：9 August 2011，
Scan for full text
Cao, B., Li, St., Li, Z. et al. Yiqi Zhuyu Decoction (益气逐瘀汤) Combined with FOLFOX-4 as first-line therapy in metastatic colorectal cancer., Chin. J. Integr. Med. 17, 593 (2011). https://doi.org/10.1007/s11655-011-0822-z

Bo Cao, Shao-tang Li, Zhi Li, et al. Yiqi Zhuyu Decoction (益气逐瘀汤) Combined with FOLFOX-4 as first-line therapy in metastatic colorectal cancer. [J]. Chinese Journal of Integrative Medicine 17(8):593-599(2011)
Cao, B., Li, St., Li, Z. et al. Yiqi Zhuyu Decoction (益气逐瘀汤) Combined with FOLFOX-4 as first-line therapy in metastatic colorectal cancer., Chin. J. Integr. Med. 17, 593 (2011). https://doi.org/10.1007/s11655-011-0822-z DOI：

Bo Cao, Shao-tang Li, Zhi Li, et al. Yiqi Zhuyu Decoction (益气逐瘀汤) Combined with FOLFOX-4 as first-line therapy in metastatic colorectal cancer. [J]. Chinese Journal of Integrative Medicine 17(8):593-599(2011) DOI： 10.1007/s11655-011-0822-z.

摘要

To evaluate the efficacy and safety of Yiqi Zhuyu Decoction (益气逐瘀汤

YZD) combined with oxaliplatin plus 5-flurouracil/leucovorin (FOLFOX-4) in the patients with metastatic colorectal cancer (MCRC). A total of 120 patients with MCRC were randomly divided into the experimental group (FOLFOX-4 plus YZD

60 cases) and the control group (FOLFOX-4 plus placebo

60 cases)

according to the sequence of hospitalization from January 2005 to December 2007. The treatment was supposed to be continued until disease progression (PD) or for 48 weeks (i.e.

up to 24 cycles of FOLFOX-4). Response rate (RR)

progression-free survival (PFS)

overall survival (OS) and adverse events (AEs) were observed. RR was 41.5% in the experimental group and 34.0% in the control group [odds ratio (OR): 1.18

95% CI: 0.77 to 1.82

P=0.432]. Median PFS were 9.0 months and 8.0 months

respectively [hazard ratio (HR): 0.78

95% CI: 0.53 to 1.15

P=0.215]. Median OS were 21.0 months and 18.0 months (HR: 0.65

95% CI: 0.43 to 0.99

P=0.043) and grade 3/4 AEs were 56.6% and 76.7% (OR: 0.61

95% CI: 0.18 to 0.87

P=0.020)

respectively. YZD combined with FOLFOX-4 chemotherapy significantly improved OS in this first-line trial in the patients with MCRC and significantly decreased grade 3/4 AEs. However

RR was not improved

and PFS did not reach statistical significance by the addition of YZD. The treatment of YZD combined with FOLFOX-4 may be necessary in order to optimize efficacy and safety.

Abstract

To evaluate the efficacy and safety of Yiqi Zhuyu Decoction (益气逐瘀汤

60 cases) and the control group (FOLFOX-4 plus placebo

60 cases)

according to the sequence of hospitalization from January 2005 to December 2007. The treatment was supposed to be continued until disease progression (PD) or for 48 weeks (i.e.

up to 24 cycles of FOLFOX-4). Response rate (RR)

progression-free survival (PFS)

overall survival (OS) and adverse events (AEs) were observed. RR was 41.5% in the experimental group and 34.0% in the control group [odds ratio (OR): 1.18

95% CI: 0.77 to 1.82

P=0.432]. Median PFS were 9.0 months and 8.0 months

respectively [hazard ratio (HR): 0.78

95% CI: 0.53 to 1.15

P=0.215]. Median OS were 21.0 months and 18.0 months (HR: 0.65

95% CI: 0.43 to 0.99

P=0.043) and grade 3/4 AEs were 56.6% and 76.7% (OR: 0.61

95% CI: 0.18 to 0.87

P=0.020)

respectively. YZD combined with FOLFOX-4 chemotherapy significantly improved OS in this first-line trial in the patients with MCRC and significantly decreased grade 3/4 AEs. However

RR was not improved

and PFS did not reach statistical significance by the addition of YZD. The treatment of YZD combined with FOLFOX-4 may be necessary in order to optimize efficacy and safety.

关键词

colorectal cancerchemotherapyFOLFOX-4Chinese MedicineYiqi Zhuyu Decoction

Keywords

colorectal cancerchemotherapyFOLFOX-4Chinese MedicineYiqi Zhuyu Decoction

references

Weitz J, Koch M, Debus J, Hohler T, Galle PR, Buchler MW. Colorectal cancer. Lancet 2005;365:153–165.

Arnold CN, Goel A, Blum HE, Boland CR. Molecular pathogenesis of colorectal cancer. Cancer 2005;104:2035–2047.

Lorenz M, Staib-Sebler E, Hochmuth K, Lorenz M, Staib-Sebler E, Hochmuth K, et al. Surgical resection of liver metastases of colorectal carcinoma: short and long-term results. Semin Oncol 2000;27:112–119.

Goldberg RM, Sargent DJ, Morton RF, Fuchs CS, Ramanathan RK, Williamson SK, et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2004;22:23–30.

Grothey A, Sargent D. Overall survival of patients with advanced colorectal cancer correlates with availability of fluorouracil, irinotecan, and oxaliplatin regardless of whether doublet or single-agent therapy is used first line. J Clin Oncol 2005;23:9441–9442.

Hicklin DJ, Ellis LM. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 2005;23:1011–1027.

Jain RK, Duda DG, Clark JW, Loeffler JS. Lessons from phase III clinical trials on anti-VEGF therapy for cancer. Nature Clin Pract Oncol 2006;3:24–40.

Saltz LB, Clarke S, Díaz-Rubio E, Scheithauer W, Figer A, Wong R, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 2008;26:2013–2019.

Sanoff HK, Sargent DJ, Campbell ME, Morton RF, Fuchs CS, Ramanathan RK, et al. Five-year data and prognostic factor analysis of oxaliplatin and irinotecan combinations for advanced colorectal cancer: n9741. J Clin Oncol 2008;26:5721–5727.

Ohtani H, Arimoto Y, Nishio K, Kanamiya Y, Oba H, Adachi K, et al. Efficacy and toxicity of fluorouracil, leucovorin plus oxaliplatin (FOLFOX4 and modified FOLFOX6) followed by fluorouracil, leucovorin plus irinotecan (FOLFIRI) for advanced or metastatic colorectal cancer-case studies. Gan To Kagaku Ryoho 2008;35:1769–1774.

Matsumoto S, Nishimura T, Kanai M, Mori Y, Nagayama S, Kawamura J, et al. Safety and efficacy of modified FOLFOX6 for treatment of metastatic or locally advanced colorectal cancer. A single-institution outcome study. Chemotherapy 2008;54:395–403.

Rothenberg ML, Cox JV, Butts C, Navarro M, Bang YJ, Goel R, et al. Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/folinic acid plus oxaliplatin (FOLFOX-4) as second-line therapy in metastatic colorectal cancer: a randomized phase III noninferiority study. Ann Oncol 2008;19:1720–1726.

Cassidy J, Clarke S, Díaz-Rubio E, Scheithauer W, Figer A, Wong R, et al. Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer. J Clin Oncol 2008;26:2006–2012.

Omura K. Advances in chemotherapy against advanced or metastatic colorectal cancer. Digestion 2008;77:13–22.

Zhao JG, Qiu F, Xiong JP, Zhang L, Xiang XJ, Yu F. A phase II trial of modified FOLFOX as first-line chemotherapy in advanced colorectal cancer. Anticancer Drugs 2007;18:1103–1107.

Liu YX, Jiang SJ, Kuang TH, Yao YW, Yang JW. Clinical observation of Yiqi Bushen Oral Liquid to the patients with carcinoma of large intestine’s metabasis and relapse after operation. Chin Arch Tradit Chin Med (Chin) 2007;25:1072–1073.

Li HJ, Dong L, Fu SY, Li Y. Comparative study on treatment of advanced colorectal cancer by Aidi Injection combined with FOLFOX4 regimen and by FOLFOX4 regimen alone. Chin J Integr Tradit West Med (Chin) 2007;27:1086–1089.

Ma J, Wang GH, Cai DF, Fan Y, Gu XX. Clinical observation of “Jianpi Xiaoliu Decoction” in preventing postoperative colorectal carcinoma recurrence and metastasis. Shanghai J Tradit Chin Med (Chin) 2005;39:24–25.

Liu J, Wang WP, Zhou YY, FANG ZY, HOU FG. Observation on therapeutic effect of Jianpi Huoxue herbs combined with chemotherapy in treating post-operational colonic cancer patients. Chin J Integr Tradit West Med (Chin) 2005;25:207–209.

Hu FS, Zhang Q, Wang XM, Yang GW, Zhao WS. Clinical study of Guben Xiaoliu Capsule combined with FOLFOX4 regimen in treating advanced colorectal cancer. Chin J Inf Tradit Chin Med (Chin) 2007;14 (7):13–14.

LI HS, LI HH, TANG ZJ. Effect of Chang’ai Kangfu Decoction on immunity in postoperational patients with large intestine cancer. Chin J Integr Tradit West Med (Chin) 2000;20:580–582.

Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205–216.

Trotti A, Colevas AD, Setser A, Rusch V, Jaques D, Budach V, et al. CTCAE v3.0: development of a comperehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol 2003;13:176–181.

Wang WP, Wang CJ. Traditional Chinese medicine for colorectal tumor metastasis understanding and countermeasures. Chin Arch Tradit Chin Med (Chin) 2002;(20):41–43.

Jia XQ, Huang NJ, Qiu HZ. Colorectal cancer metastasis “stasis poison preach homes” pathogenesis of preliminary theoretical framework. Liaoning Tradit Chin Med (Chin) 2008;35:703–705.

Chi H, Kim DH, Ji GE. Transformation of ginsenosides Rb2 and Rc from Panax ginseng by food microorganisms. Biol Pharm Bull 2005;28:2102–2105.

Lee SJ, Sung JH, Lee SJ, Moon CK, Lee BH. Antitumor activity of a novel ginseng saponin metabolite in human pulmonary adenoeareinoma cells resistant to cisplatin. Cancer Lett 1999;144:39–43.

Choi HH, Jong HS, Park JH, Choi S, Lee JW, Kim TY. A novel ginseng saponin metabolite induces apoptosis and downregulates fibroblast growth factor receptor 3 in myeloma cells. Int J Oncol 2003;23:1087–1093.

Wakabayashi C, MuraKami K, Hasegawa H. An intestinal bacterial metabolite of ginseng protopanaxadiol saponins has the ability to induce apoptosis in tumor cells. Biochem Biophys Res Comman 1998;246:725–730.

Lee SJ, Ko WG, Kim JH, Sung JH, Moon CK, Lee BH. Induction of apoptosis by a novel intestinal metabolite of ginseng saponin via cytochrome c mediated activation of caspase-3 protease. Biochem Pharmacol 2000;60:677–685.

Zhan G, Feng LY. Effect of matrine on apoptosis and Bad expression of colorectal cancer cells in vitro. Chongqing Med (Chin) 2009;38:925–927.

Chen MW, Ni l, Zhao XG, Niu XY. Research of Ginseng saponins Rg3 inhibiting protein expression of tumor blood vessels growth control factor. Chin J Chin Mater Med (Chin) 2005;30:357–360.

Yue PY, Wong DY, Wu PK, Leung PY, Mak NK, Yeung HW, et al. The angiosuppressive effects of 20(R)-gineenoside Rg3. Biochem Pharmacol 2006;72:437–445.

Xu DJ, Chen MM. function and mechanism of Astragalus polysaccharides to inhibit tumor. Chin J Hospital Pharm (Chin) 2005;25:923–925.

Gu JC, Yu WB, Wang Y, Zhang ZT, Qu Z. Astragalus polysaccharide inhibits MA2981 growth and HSP70 expression on TA2 mice. Chin J Cancer Prev Treat (Chin) 2006;13:1534–1537.

Xu G, Huang W, Zhang WM, Lai ZS, He MR, Wang YD, et al. Effect of combined use of curcumin and catechin on cyclooxygenase-2 (COX-2) mRNA in dimethylhydrazine (DMH)-induced rat colon carcinogenesis. J First Milit Med Univ (Chin) 2005;25:48–52.

Zhang JR. The effect of curcumin on growth and apoptosis of human colon carcinoma cell in vitro. Chin Arch Tradit Chin Med (Chin) 2008,26:1284–1286.

Chen JX, Wang D, Wang J, Yu HB. Effects of Yiye Baijiang Zonggan Tablets on apoptosis of human colon cancer HT-29 cells. Chin J Hosp Pharm (Chin) 2007;27:159–161.

Yee C, Riddell SR, Greenberg PD. Prospects for adoptive T cell therapy. Curr Opin Immuno 1997;9:702–708.

FULL TEXT LINK

More>

Views

963

Downloads

CSCD

Alert me when the article has been cited

Submit

Tools

Publicity Resources

Effects of Jianpi Jiedu Recipe (健脾解毒方) on reversion of P-glycoprotein-mediated multidrug resistance through COX-2 pathway in colorectal cancer

The treatment of non-small cell lung cancer by interstitial I-125 seeds implantation combined with chemotherapy and Chinese medicine

In Vitro and In Vivo inhibitory effect of the combination of Wenxia Changfu Formula (温下肠腑方) with cisplatin in non-small cell lung cancer

Chinese medicine for outcomes in colorectal cancer patients: A retrospective clinical study

Clinical observation of Shuanghuang Shengbai Granule (双黄升白颗粒) on prevention and treatment of myelosuppression caused by chemotherapy in cancer patients

Related Author

No data

Related Institution

Department of Medical Oncology, Shuguang Hospital & Putuo Hospital, Shanghai University of Traditional Chinese Medicine

Department of Molecular Oncology, H. Lee Moffitt Cancer Center and Research Institute

Department of Biomedical Sciences, Cornell University, Ithaca

Department of Chemistry, University of South Florida

Department of Traditional Chinese Medicine, Chinese People’s Liberation Army General Hospital

Address：1 Caochang, xiyuan, Beijing, People's Republic of China Postal code：100091
Tel：010-62886827, 62877592 Fax：010-62874291
Technical support is provided by Beijing Founder electronics co., LTD 京ICP备05067934号-1 京公网安备11010802024621
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰